The most common clinicopathological characteristics of the patients were invasive ductal carcinoma (69.3%), clinical stage II (44.6%), estrogen receptor positivity (45.5%), progesterone receptor positivity (46.3%), HER2 receptor negativity (52.8%), and Luminal A molecular subtype (39%) (Table 1). Here, PGR is linked to invasive ductal breast carcinoma.